Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans

Argenx stock fell early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart. The post Argenx Slumps On Mixed Third Quarter, Surprise Vyvgart Testing Plans appeared first on Investor's Business Daily.